ERAS protocols are widely applied during perioperative periods for different diseases, and there are few reports of ERAS in patients undergoing ESS. The researchers aimed to evaluate the benefits of ERAS protocol compared to regular care following ESS.
Researchers prospectively assigned a total of fifty-five patients with chronic rhinosinusitis undergoing ESS to 1 of 5 treatment groups. The ERAS groups with postoperative intravenous Flubiprofen Axetil or analgesia pump, regular care with Flurbiprofen Axetil or analgesia pump (NERAS groups), or standard care without postoperative intravenous analgesia group (control). All patients completed the Kolcaba General Comfort Questionnaire, Medical Outcomes Study Sleep Scale, and Self-rating Anxiety Scale at admission and before discharge. Researchers recorded pain scores and adverse reactions to analgesics at 2, 6, 24, 48 hours post-surgery.
Pain alleviated from 6 hours postsurgery in the ERAS group compared to 2 days in the NERAS group. Patients using opioids experienced more adverse nausea events than patients using only NSAIDs.
The study concluded that patient-tailored ERAS programs following ESS might help higher general comfort and alleviate perioperative anxiety compared with traditional perioperative care. Adequate postoperative analgesia with NSAIDs in ERAS protocol may relieve pain earlier with fewer adverse reactions.